Journal of the European Academy of Dermatology and Venereology : JEADV

How GLP-1RA drugs may affect inflammatory skin diseases

Updated

Abstract

Glucagon-like peptide 1 receptor agonists () may improve psoriasis and hidradenitis suppurativa through their effects on inflammation.

  • GLP-1RA are used in the treatment of type 2 diabetes and obesity, contributing to glucose control and weight loss.
  • These agents are associated with reductions in cardiovascular risk and have immunological and anti-inflammatory effects.
  • GLP-1RA could reduce systemic inflammation, which may help improve inflammatory skin diseases.
  • The review includes clinical data showing positive effects of GLP-1RA in patients with psoriasis and hidradenitis suppurativa.
  • Direct interactions with inflammation and immune cell signaling pathways are discussed as mechanisms of action for GLP-1RA.

Simplified

Key numbers

>15
Improvement in
Observed in patients treated with for T2DM.
5.9 ± 4.6% to 2.9 ± 3.5%
Reduction in γδ T cells
Measured before and after treatment with .
14 patients
Significant improvement in severity
Reported in a study of obese patients receiving liraglutide.

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

SAP has received honoraria for lectures or support for scientific meetings from Novo Nordisk and Lilly. Other authors have no relevant conflict of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free